Dr Debra Patt Highlights Payer, Education Considerations in Use of Trastuzumab Deruxtecan for HER2-Low Breast Cancer

According to Debra Patt, MD, PhD, MBA, Executive Vice President, Public Policy, Payer Relations, and Strategic Initiatives at Texas Oncology, results from the DESTINY-Breast04 clinical trial continue to make waves in breast cancer care—while raising considerations for payers and a need for education among doctors. Dr. Patt offered the keynote address at ASCO’s Patient-Centered Oncology Care®, highlighting the dramatic responses seen with trastuzumab deruxtecan in the trial.

Click here to read the full article.